Nat Jones of PCCA's Clinical Services Team discusses the clinical data about the efficacy of Permeation-enhanced topical pain therapy (PETPT) or transdermal pain therapy. He provides a brief history of transdermal pain therapy and evidence of the levels of efficacy PETPT has within medicine.

As long as COVID-19 is spreading in communities, everyone is encouraged to practice social distancing and face-covering, regular and thorough hand hygiene, appropriate respiratory hygiene, and good disinfection habits. PCCA Science has been researching published literature and would like to discuss what evidence is currently available regarding the questions revolving around hygiene, social distancing, and good disinfection habits.

Yi Liu, PCCA Research Pharmacist, provides an exciting update regarding new therapies, the extension of beyond-use dates (BUDs) for compounding formulations, evaluating compounding equipment and a whole lot more in this PCCA Science Update!

In the first part of this article, Pamela, Nat, and Sara shined a light on new health risk information compounders should consider when providing bioidentical hormone replacement therapy. In this second part of the article, they dive deeper into the BHRT conversation, discussing compounded topical estrogen as an option.

Compounded bioidentical hormone replacement therapy (BHRT) is an important treatment option for women around the world. Colleagues and patients alike come to PCCA experts Pamela Smith, Nat Jones and Sara Hover for guidance. In this article, our three experts cover this all-too-important topic in the HRT conversation, on what current literature says about the usage of oral vs. topical estrogen discussion.

Yi Liu, PharmD, PhD, PCCA Research Pharmacist has an exciting PCCA Science update on case studies, new product testing and comprehensive formula analysis revolving around our PCCA bases. Check it out!

We have developed a robust system to ensure that we create and maintain over 9,000 formulas that provide PCCA members with what they need to compound high-quality, pharmaceutically elegant customized medications for their patients — all while complying with the latest standards in pharmacy compounding. But what does that look like? What’s in a PCCA formula? Let's take a closer look.

PCCA Science is at the forefront of compounding research and development. Yi Liu, PhD, a PCCA research pharmacist, walks us through a few recent and exciting developments from the PCCA Science division.

June has some exciting guests including: Sara Hover, RPh and Deborah Clark, BSPharm, RPh, both from PCCA's Clinical Compounding group. Sara joined Seb and Mike to talk about how compounders can help with autoimmune disorders and Deborah discussed compounding for the veterinary world. Those topics, and so much more, are waiting for you on the latest episodes of The Mortar & Pestle.

Periorbital hyperpigmentation is caused by various external and internal factors, which makes it very complex to treat, but PCCA's Sara Hover, RPh, FAARM, discusses treatment options unique to personalized medicine that may help compounding pharmacies treat patients with this skin disorder.